POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)
Clinical trials for POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) explained in plain language.
Never miss a new study
Get alerted when new POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) trials appear
Sign up with your email to follow new studies for POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug could mean fewer shots for PCV patients
Disease control Recruiting nowThis Phase 3 trial tests faricimab (Vabysmo) in 50 people with a type of age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if a personalized treat-and-extend schedule can keep the eye healthy while allowing longer breaks between i…
Matched conditions: POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)
Phase: PHASE3 • Sponsor: Yeungnam University College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New eye drug regimen could mean fewer shots for PCV patients
Disease control Recruiting nowThis phase 3 trial is testing a personalized treatment plan using high-dose aflibercept (8 mg) for people with polypoidal choroidal vasculopathy (PCV), a condition that causes vision loss. The goal is to see if adjusting the injection schedule based on each person's response can …
Matched conditions: POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)
Phase: PHASE3 • Sponsor: Yeungnam University College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC